Elevated odds of metabolic syndrome in psoriasis: A population-based study of age and sex differences

British Journal of Dermatology

Volumn 172, Issue 2, 2015, Pages 419-427

  Danielsen, K ^a,b   Wilsgaard, T ^b   Olsen, A O ^c,d   Eggen, A E ^b   Olsen, K ^a,b   Cassano, P A ^e,f   Furberg, A S ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e Department of Obstetrics Gynecology   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL OBESITY; ADULT; AGE; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; SEX DIFFERENCE; AGE DISTRIBUTION; COMPLICATION; MIDDLE AGED; NORWAY; RISK FACTOR; SEX RATIO; VERY ELDERLY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NORWAY; PREVALENCE; PSORIASIS; RISK FACTORS; SEX DISTRIBUTION;

EID: 84922832536     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13288     Document Type: Article

References (57)

1. Love TJ, Qureshi AA, Karlson EW, et al,. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011; 147: 419-24.
2. Langan SM, Seminara NM, Shin DB, et al,. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132: 556-62.
3. Armstrong AW, Harskamp CT, Armstrong EJ,. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013; 68: 654-62.
4. Goldminz AM, Buzney CD, Kim N, et al,. Prevalence of the metabolic syndrome in children with psoriatic disease. Pediatr Dermatol 2013; 30: 700-5.
5. Alberti KG, Eckel RH, Grundy SM, et al,. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
6. Wilson PW, D'Agostino RB, Parise H, et al,. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-72.
7. Finucane MM, Stevens GA, Cowan MJ, et al,. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-67.
8. Icen M, Crowson CS, McEvoy MT, et al,. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol 2009; 60: 394-401.
9. Danielsen K, Olsen AO, Wilsgaard T, Furberg AS,. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol 2013; 168: 1303-10.
10. Ding X, Wang T, Shen Y, et al,. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol 2012; 22: 663-7.
11. Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H,. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol 2010; 62: 979-87.
12. Bo K, Thoresen M, Dalgard F,. Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults. Dermatology 2008; 216: 40-5.
13. Jensen P, Thyssen JP, Zachariae C, et al,. Cardiovascular risk factors in subjects with psoriasis: a cross-sectional general population study. Int J Dermatol 2013; 52: 681-3.
14. Ryan C, Korman NJ, Gelfand JM, et al,. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol 2013; 70: 146-67.
15. Helmick CG, Sacks JJ, Gelfand JM, et al,. Psoriasis and psoriatic arthritis: a public health agenda. Am J Prev Med 2013; 44: 424-6.
16. Miller IM, Ellervik C, Yazdanyar S, Jemec GB,. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 2013; 69: 1014-24.
17. Nijsten T, Wakkee M,. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 2009; 129: 1601-3.
18. Stern RS, Nijsten T,. Going beyond associative studies of psoriasis and cardiovascular disease. J Invest Dermatol 2012; 132: 499-501.
19. Friedewald VE, Cather JC, Gelfand JM, et al,. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 2008; 102: 1631-43.
20. Kimball AB, Gladman D, Gelfand JM, et al,. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-42.
21. Dowlatshahi EA, Kavousi M, Nijsten T, et al,. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. J Invest Dermatol 2013; 133: 2347-54.
22. Li WQ, Han JL, Manson JE, et al,. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol 2012; 166: 811-18.
23. Gelfand JM, Neimann AL, Shin DB, et al,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
24. UiT The Arctic University of Norway. The Tromsø Study. Available at: www.tromsostudy.com (last accessed 13 December 2014).
25. Jacobsen BK, Eggen AE, Mathiesen EB, et al,. Cohort profile: the Tromsø Study. Int J Epidemiol 2012; 41: 961-7.
26. Eggen AE, Mathiesen EB, Wilsgaard T, et al,. The sixth survey of the Tromsø Study (Tromsø 6) in 2007-08: collaborative research in the interface between clinical medicine and epidemiology: study objectives, design, data collection procedures, and attendance in a multipurpose population-based health survey. Scand J Public Health 2013; 41: 65-80.
27. Alberti KG, Zimmet P, Shaw J,. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
28. Johnson TP, Wislar JS,. Response rates and nonresponse errors in surveys. JAMA 2012; 307: 1805-6.
29. Langhammer A, Krokstad S, Romundstad P, et al,. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Med Res Methodol 2012; 12: 143.
30. Stern RS, Nijsten T, Feldman SR, et al,. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9.
31. Armstrong AW, Schupp C, Wu J, Bebo B,. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS ONE 2012; 7: e52935.
32. Olsen AO, Grjibovski A, Magnus P, et al,. Psoriasis in Norway as observed in a population-based Norwegian twin panel. Br J Dermatol 2005; 153: 346-51.
33. Gelfand JM, Stern RS, Nijsten T, et al,. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005; 52: 23-6.
34. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
35. Gelfand JM, Weinstein R, Porter SB, et al,. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141: 1537-41.
36. Basarab T, Munn SE, Jones RR,. Diagnostic accuracy and appropriateness of general practitioner referrals to a dermatology out-patient clinic. Br J Dermatol 1996; 135: 70-3.
37. Jagou M, Bastuji-Garin S, Bourdon-Lanoy E, et al,. Poor agreement between self-reported and dermatologists' diagnoses for five common dermatoses. Br J Dermatol 2006; 155: 1006-12.
38. Kurd SK, Gelfand JM,. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009; 60: 218-24.
39. Lima XT, Minnillo R, Spencer JM, Kimball AB,. Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants. J Eur Acad Dermatol Venereol 2013; 27: 680-5.
40. Rothman KJ, Greenland S, Lash TL,. Modern Epidemiology, 3rd edn. Philadelphia: Lippincott, Williams & Wilkins, 2008.
41. Carr DB, Utzschneider KM, Hull RL, et al,. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087-94.
42. Vega GL, Adams-Huet B, Peshock R, et al,. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab 2006; 91: 4459-66.
43. Wilsgaard T, Arnesen E,. Change in serum lipids and body mass index by age, sex, and smoking status: the Tromsø study 1986-1995. Ann Epidemiol 2004; 14: 265-73.
44. Gelfand JM, Troxel AB, Lewis JD, et al,. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 493-9.
45. Xu T, Zhang YH,. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol 2012; 167: 1345-50.
46. Setty AR, Curhan G, Choi HK,. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007; 167: 1670-5.
47. Huerta C, Rivero E, Rodriguez LA,. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559-65.
48. Jensen P, Zachariae C, Christensen R, et al,. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol 2013; 149: 795-801.
49. Naldi L, Conti A, Cazzaniga S, et al,. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol 2014; 170: 634-42.
50. Buerger C, Richter B, Woth K, et al,. Interleukin-1β interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis. J Invest Dermatol 2012; 132: 2206-14.
51. Capon F, Burden AD, Trembath RC, Barker JN,. Psoriasis and other complex trait dermatoses: from loci to functional pathways. J Invest Dermatol 2012; 132: 915-22.
52. Boehncke WH, Boehncke S, Tobin AM, Kirby B,. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-7.
53. Kimball AB,. Psoriasis and cardiovascular disease: another contribution in the hierarchy of evidence. Br J Dermatol 2012; 167: 1198-9.
54. Li Y, Begovich AB,. Unraveling the genetics of complex diseases: susceptibility genes for rheumatoid arthritis and psoriasis. Semin Immunol 2009; 21: 318-27.
55. Tian S, Krueger JG, Li K, et al,. Meta-analysis derived (MAD) transcriptome of psoriasis defines the 'core' pathogenesis of disease. PLoS ONE 2012; 7: e44274.
56. Lu Y, Chen H, Nikamo P, et al,. Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol 2013; 133: 836-9.
57. Enamandram M, Kimball AB,. Psoriasis epidemiology: the interplay of genes and the environment. J Invest Dermatol 2013; 133: 287-9.